153 related articles for article (PubMed ID: 37154315)
21. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer.
Raheem AR; Abdul-Rasheed OF; Al-Naqqash MA
Saudi Med J; 2019 Dec; 40(12):1218-1226. PubMed ID: 31828273
[TBL] [Abstract][Full Text] [Related]
23. Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis.
Lee Y; Ni J; Beretov J; Wasinger VC; Graham P; Li Y
Mol Cancer; 2023 Feb; 22(1):33. PubMed ID: 36797736
[TBL] [Abstract][Full Text] [Related]
24. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
25. [Tumor markers. Personal experience--screening of breast cancer by determining CEA in nipple discharge].
Inaji H; Koyama H
Gan To Kagaku Ryoho; 1991 Feb; 18(2):313-7. PubMed ID: 1992927
[TBL] [Abstract][Full Text] [Related]
26. A new insight on serum microRNA expression as novel biomarkers in breast cancer patients.
Bahmanpour Z; Sheervalilou R; Choupani J; Shekari Khaniani M; Montazeri V; Mansoori Derakhshan S
J Cell Physiol; 2019 Nov; 234(11):19199-19211. PubMed ID: 31026062
[TBL] [Abstract][Full Text] [Related]
27. Multi-miRNA panel of tumor-derived extracellular vesicles as promising diagnostic biomarkers of early-stage breast cancer.
Kim MW; Park S; Lee H; Gwak H; Hyun KA; Kim JY; Jung HI; Il Kim S
Cancer Sci; 2021 Dec; 112(12):5078-5087. PubMed ID: 34626053
[TBL] [Abstract][Full Text] [Related]
28. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
29. Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms.
Ling L; Aldoghachi AF; Chong ZX; Ho WY; Yeap SK; Chin RJ; Soo EZX; Khor JF; Yong YL; Ling JL; Yan NS; Ong AHK
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499713
[TBL] [Abstract][Full Text] [Related]
30. Serum and Saliva Levels of Cancer Antigen 15-3, Carcinoembryonic Antigen, Estradiol, Vaspin, and Obestatin as Biomarkers for the Diagnosis of Breast Cancer in Postmenopausal Women.
Farahani H; Amri J; Alaee M; Mohaghegh F; Rafiee M
Lab Med; 2020 Nov; 51(6):620-627. PubMed ID: 32537654
[TBL] [Abstract][Full Text] [Related]
31. Mutually distinguishing microRNA signatures of breast, ovarian and endometrial cancers in vitro.
Hirschfeld M; Ge I; Rücker G; Waldschmidt J; Mayer S; Jäger M; Voigt M; Kammerer B; Nöthling C; Berner K; Weiss D; Asberger J; Erbes T
Mol Med Rep; 2020 Nov; 22(5):4048-4060. PubMed ID: 33000259
[TBL] [Abstract][Full Text] [Related]
32. Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.
Jacklyn G; McGeechan K; Irwig L; Houssami N; Morrell S; Bell K; Barratt A
Breast Cancer Res Treat; 2017 Dec; 166(3):843-854. PubMed ID: 28822001
[TBL] [Abstract][Full Text] [Related]
33. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
Tang Z; Li L; Shen L; Shen X; Ju S; Cong H
Lab Med; 2018 Oct; 49(4):323-328. PubMed ID: 29701836
[TBL] [Abstract][Full Text] [Related]
35. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
36. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.
Zhao FL; Dou YC; Wang XF; Han DC; Lv ZG; Ge SL; Zhang YK
Mol Biol Rep; 2014 Sep; 41(9):5913-22. PubMed ID: 25103018
[TBL] [Abstract][Full Text] [Related]
37. Detection of early breast cancer beyond mammographic screening: a promising biomarker panel.
Hamann M; Grill S; Struck J; Bergmann A; Hartmann O; Pölcher M; Kiechle M
Biomark Med; 2019 Sep; 13(13):1107-1117. PubMed ID: 31468986
[No Abstract] [Full Text] [Related]
38. Circulating microRNA-based screening tool for breast cancer.
Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
[TBL] [Abstract][Full Text] [Related]
39. CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis.
Tang S; Zhou F; Sun Y; Wei L; Zhu S; Yang R; Huang Y; Yang J
Breast Cancer; 2016 Nov; 23(6):813-819. PubMed ID: 26898373
[TBL] [Abstract][Full Text] [Related]
40. 8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.
Nour Eldin EEM; El-Readi MZ; Nour Eldein MM; Alfalki AA; Althubiti MA; Mohamed Kamel HF; Eid SY; Al-Amodi HS; Mirza AA
Clin Breast Cancer; 2019 Apr; 19(2):e385-e393. PubMed ID: 30683611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
